IRVINE, Calif., Aug. 24, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s initial public offering on January 30, 2015 (the “IPO”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.
If you purchased Avinger shares on or about the IPO, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, Avinger filed documents in connection with the IPO that contained materially false and misleading statements and/or failed to disclose: that Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; that the Company already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; that physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products compared to competing products and procedures available in the market; that Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and that as a result, the Company was experiencing lower sales and revenues. When this information was released, Avinger’s share price dropped, causing investors harm according to the Complaint. On May 3, 2017, the stock closed at $0.57 per share, a decline of over 95% from the IPO price.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Anta Sports Expands Global Footprint With Strategic Puma Stake
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Washington Post Publisher Will Lewis Steps Down After Layoffs
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



